<DOC>
	<DOCNO>NCT00465270</DOCNO>
	<brief_summary>The purpose study investigate whether percutaneous Patent Foramen Ovale ( PFO ) closure , use AMPLATZER PFO Occluder , superior current standard care medical treatment prevention recurrent embolic stroke .</brief_summary>
	<brief_title>RESPECT PFO Clinical Trial</brief_title>
	<detailed_description>The AMPLATZER PFO Occluder percutaneous , transcatheter occlusion device intend non-surgical closure patent foramen ovale subject cryptogenic stroke due presumed paradoxical embolism within last 270 day .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Subjects cryptogenic stroke within last 270 day Subjects diagnosed Patent Foramen Ovale ( PFO ) Subjects willing participate followup visit Subjects intracardiac thrombus tumor Subjects acute recent ( within 6 month ) myocardial infarction unstable angina Subjects leave ventricular aneurysm akinesis Subjects atrial fibrillation/atrial flutter ( chronic intermittent ) Subjects another source right leave shunt identify baseline , include atrial septal defect and/or fenestrated septum Subjects contraindication aspirin Clopidogrel therapy Pregnant desire become pregnant within next year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cryptogenic</keyword>
	<keyword>Stroke</keyword>
	<keyword>PFO</keyword>
</DOC>